- TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling
-
Chen Y, Zhao J, Li D, Hao J, He P, Wang H, Zhang M
- KMID: 2418847
- Yonsei Med J.
- 2018 Jan;59(1):43-50.
- doi: 10.3349/ymj.2018.59.1.43
PURPOSE: Tripartite-motif-containing protein 56 (TRIM56) has been found to exhibit a broad antiviral activity, depending upon E3 ligase activity. Here, we attempted to evaluate the function of TRIM56 in multiple... -
- CITED
-
- Close
- SHARE
-
- Close
- Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells
-
Park SN, Noh KT, Jeong YI, Jung ID, Kang HK, Cha GS, Lee SJ, Seo JK, Kang DH, Hwang TH, Lee EK, Kwon B, Park YM
- KMID: 2154227
- Exp Mol Med.
- 2013 Feb;45(2):e8.
We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin... -
- CITED
-
- Close
- SHARE
-
- Close
- Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts
-
Park MK, Oh HJ, Heo YM, Park EM, Cho ML, Kim HY, Park SH
- KMID: 1022119
- Exp Mol Med.
- 2011 Aug;43(8):446-454.
- doi: 10.3858/emm.2011.43.8.050
Indoleamine 2,3-dioxygenase (IDO) is a key negative regulator of immune responses and has been implicated in tumor tolerance, autoimmune disease and asthma. IDO was detected in the joint synovial tissue... -
- CITED
-
- Close
- SHARE
-
- Close
